ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
… QR-313 was granted ODD in the U.S. and Europe. Axiomer ® RNA-editing technology was introduced at the Company’s second … QR-313 ready for clinical trials and validating our novel RNA-editing technology, Axiomer ® ,” said Daniel A. de Boer, … to future milestones and royalties. Axiomer ® RNA editing technology platform In June, ProQR introduced its …
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022
Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing pla
… into a research collaboration to apply the Axiomer ® RNA editing technology to fibrosis targets selected by … loss associated with Usher syndrome type 2A. ADAR A-to-I RNA editing expert Dr. Peter A. Beal was appointed to ProQR’s … of RNA-based therapeutics, particularly in the area of RNA editing. As an expert in the field of ADAR and A-to-I …
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators and pr
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome